for etoricoxib 90 mg til indikationerne reumatoid artritis og ankyloserende spondylitis er positivt, men i forbindelse med den kardiorenale sikkerhed er produktresuméets og indlægssedlens afsnit om kontraindikationer og advarsler blevet revideret -
dose in the RA and AS indications is positive; however, revisions to the contraindications and warnings sections have been added to the summary of product characteristics and package leaflet in relation to cardiorenal safety.